The Felsenstein Medical Research Center
TOPIC

Laboratory of Experimental Pharmacology and Oncology

Head of Laboratory: Ada Rephaeli, Ph.D.

  Tel: 972-3-9376126
Fax: 972-3-9228096
E-mail: adarep@post.tau.ac.il

Research Topics

  1. The anticancer activity of histone deacetylase inhibitors (HDACIs).

  2. The interaction between HDACIs-prodrugs and anticancer treatment.

  3. Protection of normal cells and organs by HDAC inhibitors.

  4. Modulation of the histone code by the HDACIs.

  5. GABA derivatives uses for the treatment of neurological disorders

Selected Publications

  1. Geffen Y, Nudelman A, Gil-Ad I, Rephaeli A., Huang M, Savitsky K, Klapper L, Winkler I, Meltzer HY, Weizman A. BL-1020: A novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia. Eur Neuropsychopharmacol 10:1-13, 2009. MEDLINE

  2. Tarasenko N, Kessler-Icekson G, Boer P, Inbal A, Schlesinger H, Phillips DR, Cutts SM, Nudelman A, Rephaeli A. The histone deacetylase inhibitor butyroyloxymethyl diethylphosphate (AN-7) protects normal cells against toxicity of anticancer agents while augmenting their anticancer activity. Invest New Drugs. 30(1):130- 43, 2012. MEDLINE

  3. Tarasenko N, Cutts SM, Phillips DR, Inbal A, Nudelman A, Kessler-Icekson G, Rephaeli A. Disparate impact of butyroyloxymethyl diethylphosphate (AN-7), a histone deacetylase inhibitor, and doxorubicin in mice bearing a mammary tumor. PLoS One. ;7:e31393, 2012. MEDLINE

  4. Berkovitch-Luria G, Weitman M, Nudelman A, Rephaeli A, Malik Z. Multifunctional 5-aminolevulinic acid prodrugs activating diverse cell-death pathways. Invest New Drugs. ;30:1028-38, 2012. MEDLINE

  5. Forrest RA, Swift LP, Rephaeli A, Nudelman A, Kimura K, Phillips DR, Cutts SM. Activation of DNA damage response pathways as a consequence of anthracycline-DNA adduct formation. Biochem Pharmacol;83(12):1602-12, 2012. MEDLINE